Aging Clinical Trial
Official title:
Chang Gung Memorial Hospital, Taipei, Taiwan
Photoaging is characterized by cellular changes and alterations in dermal extracellular matrix proteins with degeneration of connective tissue caused by intrinsic and extrinsic factors. The clinical manifestations of photoaging included wrinkles, pigmented changes, tissue loss, and sagging. Autologous platelet-rich plasma is a preparation of platelets in concentrated plasma from peripheral blood. The α granules of platelets contained many growth factors. According to previous literature, growth factors in platelet-rich plasma directly stimulate fibroblast proliferation to boost collagen production. It has also been shown to modulate extracellular matrix metabolism and remodeling by increasing the expression of specific matrix metalloproteinases. In review of previous literatures, there was only limited researches of platelet-rich plasma for treatment of photoaging. Therefore, the present study was conducted for analyzing the efficacy and safety of autologous platelet-rich plasma in photoaging therapy.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | August 31, 2022 |
Est. primary completion date | August 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion criteria: 1. Men or female patients older than 20 years old with facial photoaging (Glogau Scale type II) 2. The photoaging severity of bilateral face is symmetric. Exclusion criteria: 1. Patients with thrombocytopenia, coagulopathy, hematopoietic malignancy. 2. Patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history. 3. Patients had received laser, radiofrequency, ultherapy over treated area within 6 months. 4. Patients had received botulism or filler injection over treated area within 12 months. 5. Patients had received plastic surgery over treated area within 12 months. 6. Patients had severe psychiatric disorders with poor control. 7. Patients with other diseases which are not suitable for receiving platelet rich plasma (PRP) injection therapy. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Memorial Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML. Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg. 2017 Jun;43(6):826-835. doi: 10.1097/DSS — View Citation
Elnehrawy NY, Ibrahim ZA, Eltoukhy AM, Nagy HM. Assessment of the efficacy and safety of single platelet-rich plasma injection on different types and grades of facial wrinkles. J Cosmet Dermatol. 2017 Mar;16(1):103-111. doi: 10.1111/jocd.12258. Epub 2016 — View Citation
Lee ZH, Sinno S, Poudrier G, Motosko CC, Chiodo M, Saia W, Gothard D, Thomson JE, Hazen A. Platelet rich plasma for photodamaged skin: A pilot study. J Cosmet Dermatol. 2019 Feb;18(1):77-83. doi: 10.1111/jocd.12676. Epub 2018 May 31. — View Citation
Mehryan P, Zartab H, Rajabi A, Pazhoohi N, Firooz A. Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow's feet wrinkles. J Cosmet Dermatol. 2014 Mar;13(1):72-8. doi: 10.1111/jocd.12072. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global Aesthetic Improvement Scale | To assess the global aesthetic improvement in appearance compared to pretreatment (minimum: -1, worse; maximum: 3, very much improved) | 3 months after the last session of treatment | |
Primary | Fitzpatrick wrinkle scale | To assess the severity of wrinkles of photoaging areas (minimum: 1, mild; maximum: 9, severe) | 3 months after the last session of treatment | |
Primary | Wrinkle Severity Rating scale | To assess the severity of wrinkles of photoaging areas (minimum: 1, absent; maximum: 5, extreme) | 3 months after the last session of treatment | |
Secondary | The scores of rhytids in VISIA system | Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe) |
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment | |
Secondary | The scores of texture in VISIA system | Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe) |
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment | |
Secondary | The scores of pores size in VISIA system | Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe) |
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment | |
Secondary | The scores of pigment spots in VISIA system | Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe) |
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment | |
Secondary | The scores of brownish spots in VISIA system | Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe) |
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |